Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements (Details)

v3.19.3
Royalty Purchase Agreements (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 26, 2019
USD ($)
Apr. 07, 2019
USD ($)
Feb. 25, 2019
USD ($)
Agreement
Sep. 20, 2018
USD ($)
LicensedProduct
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Royalty Purchase Agreement [Line Items]                
Long-term royalty receivables         $ 34,375,000 $ 34,375,000 $ 34,375,000 $ 15,000,000 [1]
Changes in estimated fair value of contingent consideration             0  
Payments of contingent consideration           0    
Royalty Purchase Agreement [Member]                
Royalty Purchase Agreement [Line Items]                
Long-term royalty receivables         34,375,000 34,375,000 34,375,000 15,000,000
Impairment related to long-term royalty receivable             0  
Royalty Purchase Agreement [Member] | Agenus [Member]                
Royalty Purchase Agreement [Line Items]                
Payments to acquire milestones and royalties             15,000,000  
Long-term royalty receivables         15,000,000 15,000,000 15,000,000 15,000,000
Impairment related to long-term royalty receivable             0 $ 0
Royalty Purchase Agreement [Member] | Agenus [Member] | Silicon Valley Bank [Member]                
Royalty Purchase Agreement [Line Items]                
Loan borrowed         7,500,000 7,500,000 7,500,000  
Royalty Purchase Agreement [Member] | Agenus [Member] | Incyte [Member]                
Royalty Purchase Agreement [Line Items]                
Number of licensed products related to milestone and royalties | LicensedProduct       6        
Royalty Purchase Agreement [Member] | Agenus [Member] | Merck [Member]                
Royalty Purchase Agreement [Line Items]                
Number of licensed products related to milestone and royalties | LicensedProduct       1        
Royalty Purchase Agreement [Member] | Agenus [Member] | Incyte and Merck [Member]                
Royalty Purchase Agreement [Line Items]                
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones       $ 59,500,000        
Royalty Purchase Agreement [Member] | Agenus [Member] | Right to Receive Low-Single Mid-Teen Royalties [Member] | Incyte [Member]                
Royalty Purchase Agreement [Line Items]                
Purchased percentage of royalties on net sales of products       33.00%        
Purchased percentage of milestones       10.00%        
Royalty Purchase Agreement [Member] | Agenus [Member] | Right to Receive Low Single Digit Royalties [Member] | Merck [Member]                
Royalty Purchase Agreement [Line Items]                
Purchased percentage of royalties on net sales of products       33.00%        
Purchased percentage of milestones       10.00%        
Royalty Purchase Agreement [Member] | Bioasis Technologies Inc [Member]                
Royalty Purchase Agreement [Line Items]                
Payments to acquire milestones and royalties             300,000  
Long-term royalty receivables     $ 400,000          
Impairment related to long-term royalty receivable             0  
Percentage of Option to purchase royalty right on future license agreements     1.00%          
Number of license agreements | Agreement     2          
Estimated fair value of contingent consideration         100,000 100,000 100,000  
Royalty Purchase Agreement [Member] | Bioasis Technologies Inc [Member] | Maximum [Member]                
Royalty Purchase Agreement [Line Items]                
Potential future cash payments         200,000 $ 200,000 $ 200,000  
Royalty Purchase Agreement [Member] | Aronora [Member]                
Royalty Purchase Agreement [Line Items]                
Long-term royalty receivables   $ 9,000,000            
Potential future cash payments   3,000,000            
Payments of contingent consideration   $ 3,000,000     $ 3,000,000      
Expected reduction in purchased percentage of non-royalties on net sales of products   5.00%            
Upfront payment   $ 6,000,000            
Milestones payments to aggregate amount of per product   85,000,000            
Received cumulative royalties on net sales per product amount   250,000,000            
Royalty Purchase Agreement [Member] | Aronora [Member] | Term Loan [Member]                
Royalty Purchase Agreement [Line Items]                
Upfront payment   3,000,000            
Royalty Purchase Agreement [Member] | Aronora [Member] | Maximum [Member]                
Royalty Purchase Agreement [Line Items]                
Potential future cash payments   $ 1,000,000            
Royalty Purchase Agreement [Member] | Aronora [Member] | Bayer Products [Member]                
Royalty Purchase Agreement [Line Items]                
Purchased percentage of royalties on net sales of products   100.00%            
Purchased percentage of non-royalties on net sales of products   10.00%            
Royalty Purchase Agreement [Member] | Aronora [Member] | Non-Bayer Products [Member]                
Royalty Purchase Agreement [Line Items]                
Purchased percentage of non-royalties on net sales of products   10.00%            
Royalty Purchase Agreement [Member] | Palobiofarma, S.L {Member]                
Royalty Purchase Agreement [Line Items]                
Payments to acquire milestones and royalties $ 10,000,000              
Long-term royalty receivables 10,000,000              
Royalty Purchase Agreement [Member] | Palobiofarma, S.L {Member] | Silicon Valley Bank [Member]                
Royalty Purchase Agreement [Line Items]                
Loan borrowed $ 5,000,000              
Royalty Purchase Second License Agreement [Member] | Bioasis Technologies Inc [Member] | Maximum [Member]                
Royalty Purchase Agreement [Line Items]                
Obligation upon exercise of options per licensed product     $ 300,000          
Royalty Purchase Third License Agreement [Member] | Bioasis Technologies Inc [Member] | Maximum [Member]                
Royalty Purchase Agreement [Line Items]                
Obligation upon exercise of options per licensed product     $ 400,000          
[1] The consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.